Endoscopic (Non-Surgical) Weight-Loss Options: ESG, Balloon, and GLP-1 Compared

Endoscopic bariatric therapy — weight-loss procedures done entirely through the mouth with a flexible endoscope, no incisions and no laparoscopy — has quietly become the middle ground between a GLP-1 injection and full bariatric surgery. The two options with the strongest evidence are endoscopic sleeve gastroplasty (ESG), which stitches the stomach into a narrow tube (about 13.6% total body weight loss at one year in the randomized MERIT trial^[1], holding near 16% at five years^[3]), and the intragastric balloon, a space-occupying device left in the stomach for six months (about 7–15% TBWL, with regain common after removal^[4][6]). For anyone comparing these against Wegovy or Zepbound, the honest framing is simple: ESG lands roughly in semaglutide's league (STEP-1: −14.9%^[7]), below tirzepatide (SURMOUNT-1: −20.9%^[8]) and well below sleeve gastrectomy or bypass (~25–30%). This is the pillar overview — how the endoscopic options compare to each other, to GLP-1 drugs, and to surgery on weight loss, durability, invasiveness, reversibility, and cost — with links out to the deep dives.

The honest summary

• Endoscopic means incisionless. All of these procedures are done through the mouth with an endoscope — no external cuts, usually outpatient, home the same day. That is the category's defining advantage over surgery and its defining difference from a GLP-1 (a procedure, not a lifelong prescription).
• ESG is the flagship, with a randomized trial behind it. The MERIT RCT (Abu Dayyeh 2022, Lancet^[1]) found 13.6% TBWL at 52 weeks versus 0.8% for lifestyle alone; pooled meta-analysis puts it at 15–17%^[2] and a five-year cohort held near 15.9%^[3]. Serious adverse events run about 2%^[2].
• The intragastric balloon is a shorter, lighter-touch bridge. A balloon is placed and removed endoscopically (or swallowed and later deflated), stays roughly six months, and produces about 7–15% TBWL while it is in — enough to clear the medical societies' adoption thresholds^[4][5] and improve obesity-related conditions^[6] — but weight is commonly regained after removal.
• Aspiration therapy and other devices exist but are niche. Aspiration therapy (a tube that drains a portion of a meal from the stomach) and endoscopic re-do procedures for post-surgical regain round out the toolkit, but they are used far less than ESG and balloons.
• On weight loss, the ladder is clear. Balloon (~7–15%) ≤ ESG (~13.6–17%) ≈ semaglutide (~14.9%^[7]) < tirzepatide (~20.9%^[8]) < surgery (~25–30%). No endoscopic option has ever been tested head-to-head against a GLP-1.
• The real trade is one-time procedure vs ongoing drug. Endoscopic procedures are single interventions with no monthly cost and no injections, but are invasive and usually paid out of pocket; a GLP-1 is non-invasive and often partly insured, but its weight loss tends to reverse if you stop. The two can be combined — ESG plus liraglutide beat ESG alone^[9].

What counts as an endoscopic weight-loss option?

“Bariatric endoscopy” covers any weight-loss procedure delivered through the working channel of a flexible endoscope passed down the throat — nothing is cut, stapled, or removed from the outside. The category was formalized when the American Society for Gastrointestinal Endoscopy and the American Society for Metabolic and Bariatric Surgery laid out a pathway and performance thresholds (the “PIVI” criteria) a therapy must clear before it is considered ready for routine use^[5]. There are two broad families:

• Restrictive/suturing procedures — ESG. A suturing platform stitches the stomach into a narrow sleeve from the inside, shrinking capacity by roughly 70%. Durable and the best-evidenced of the group. See the full ESG evidence review.
• Space-occupying devices — intragastric balloons. A silicone balloon is filled with saline or gas and left in the stomach for about six months to blunt appetite and slow emptying, then removed. A temporary tool, best thought of as a jump-start. See the gastric balloon evidence review and the balloon vs GLP-1 comparison.
• Other/emerging — aspiration therapy and revisional endoscopy. Aspiration therapy drains part of a meal through a small tube after eating; transoral outlet reduction and other re-do procedures tighten a stretched surgical pouch to treat weight regain. Useful in specific situations, not first-line for most people.

How the options compare

The table below is the decision map most people are really after. The essential caveat: no head-to-head trial pits any endoscopic option against a GLP-1, so the drug rows are cross-trial reference points, not a direct contest.

Reading across the table, five things stand out:

• ESG is the endoscopic option that competes with the drugs. Its ~13.6–17% TBWL^[1][2] overlaps semaglutide^[7] and clearly beats a balloon; it is the one to weigh seriously against a GLP-1. Read the focused ESG vs GLP-1 head-to-head.
• The balloon is a bridge, not a destination. It works while it is in and clears the PIVI thresholds^[4][5], but the six-month lifespan and post-removal regain make it best for a defined jump-start rather than a long-term answer^[6].
• Durability separates ESG from the balloon. ESG holds near 16% at five years^[3]; a balloon is gone in six months. If durability matters, ESG is the endoscopic pick.
• Tirzepatide and surgery still win on raw magnitude. If the goal is the largest possible weight loss, a potent GLP-1^[8] or a surgical sleeve/bypass out-loses every endoscopic option.
• Combination is a real strategy. An endoscopic procedure plus a GLP-1 can out-perform either alone — ESG plus liraglutide beat ESG alone in a randomized study^[9].

ESG vs the balloon: choosing within the endoscopic category

If you have already decided you want an incisionless procedure rather than a drug or surgery, the choice usually comes down to ESG vs a balloon:

• Choose ESG for more weight loss and durability — ~13.6–17% TBWL that holds for years^[1][3], a one-time suturing procedure, potentially reversible, no device to remove.
• Choose a balloon for a lower-commitment, shorter, fully reversible jump-start — useful to build momentum, kick off behavior change, or lose weight ahead of another procedure — accepting that ~7–15% loss^[4] and likely partial regain after the six-month removal^[6].
• Either way, behavior still decides the long game. Both procedures shrink or occupy the stomach; neither removes the need to change how you eat, and both pair naturally with a GLP-1 or intensive lifestyle support.

For the deeper contrasts, see ESG vs surgical sleeve gastrectomy and gastric balloon vs GLP-1.

Prefer a GLP-1 to a procedure? Top vetted providers

Endoscopic options vs GLP-1 drugs: the structural trade-offs

• Weight loss: ESG (~13.6–17%^[1][2]) rivals semaglutide^[7] but trails tirzepatide^[8]; a balloon (~7–15%^[4]) generally trails both drugs. On magnitude, the potent GLP-1 wins.
• Durability: ESG's restriction persists for years^[3]; a balloon's effect ends at removal^[6]; a GLP-1's effect lasts only as long as you keep taking it, with regain common after stopping.
• Invasiveness and risk: a GLP-1 is non-invasive (a weekly injection); endoscopic procedures are done under sedation and carry a small procedural risk — ESG serious adverse events ~2%^[2], balloon serious adverse events low but real^[6].
• Cost economics: a GLP-1 is a recurring monthly cost that is often partly insured; an endoscopic procedure is a large one-time cost usually paid out of pocket, with no recurring drug bill. Over a multi-year horizon the math can flip — see how much weight-loss procedures cost.
• Reversibility and future options: a balloon is fully reversible and ESG is largely so; because neither removes tissue, a surgical sleeve or bypass remains available later. A GLP-1 is “reversible” simply by stopping — along with its benefit.

Where surgery still fits

Endoscopic therapy does not replace surgery for everyone. Sleeve gastrectomy and gastric bypass remain the most effective, most durable options (~25–30% TBWL) with the strongest long-term metabolic and outcome data, and are frequently insurance-covered when criteria are met. Endoscopic options extend a procedural choice to people with lower BMI, those who want to avoid permanently altering their anatomy, or those who do not qualify for or do not want an operation. For the full surgical comparison, see bariatric surgery vs GLP-1s, the decision guide, and the safest form of weight-loss surgery.

Who each option suits

• ESG — adults with class 1–2 obesity (BMI ~30–40, the MERIT population^[1]) who want a durable, one-time, incisionless intervention without lifelong medication, and are willing to pay out of pocket.
• Intragastric balloon — people who want a lower-commitment, fully reversible jump-start, a defined six-month window of appetite suppression, or weight loss ahead of another procedure^[4][6].
• A GLP-1 — people who prefer a non-invasive, often partly insured option, want the largest medical weight loss (tirzepatide^[8]), or aren't ready for a procedure — accepting an ongoing prescription and regain risk if stopped.
• Surgery — higher-BMI patients or those needing maximal, most durable weight loss and diabetes benefit who accept permanently altered anatomy.
• Combination (procedure + GLP-1) — a strategy for those wanting more than either delivers alone, supported by ESG-plus-liraglutide data^[9].

What we still don't know

• No head-to-head endoscopic-vs-GLP-1 randomized trial exists. Every drug-vs-procedure figure here is cross-trial and should be read as directional.
• Long-term hard-outcome data are thinner than for surgery. ESG has solid 1-to-5-year weight and metabolic data^[1][3], but nothing like the decades of mortality and diabetes-remission evidence behind bariatric surgery.
• How endoscopic procedures best combine with the newer potent GLP-1/GIP drugs is unsettled. ESG plus liraglutide beat ESG alone^[9], but combinations with semaglutide or tirzepatide have not been established in large trials.
• Real-world balloon regain and long-term ESG durability outside expert centers remain to be fully characterized.

Bottom line

• Endoscopic (non-surgical) weight-loss options sit between GLP-1 drugs and surgery: incisionless, one-time procedures with lower risk and faster recovery than surgery, but usually paid out of pocket.
• ESG is the flagship — ~13.6% TBWL at one year in a randomized trial^[1], near 16% at five years^[3], on par with semaglutide^[7] and below tirzepatide^[8] and surgery, with ~2% serious complications^[2].
• The intragastric balloon is a six-month, fully reversible bridge (~7–15% TBWL^[4]) with common post-removal regain^[6] — a jump-start, not a destination.
• On raw weight loss, tirzepatide and surgery still win; on being a one-time, no-injection intervention, ESG wins. The two approaches can be combined^[9].
• No endoscopic option has been tested head-to-head against a GLP-1; choose on durability, invasiveness, cost horizon, reversibility, and personal fit, not on cross-trial numbers alone.

Related research

• Endoscopic sleeve gastroplasty (ESG): the evidence — the flagship endoscopic procedure in depth
• ESG vs GLP-1 (semaglutide and tirzepatide) — the focused procedure-vs-drug head-to-head
• Gastric balloon for weight loss — the six-month device reviewed
• Gastric balloon vs GLP-1 — the balloon against a weekly injection
• ESG vs surgical sleeve gastrectomy — endoscopic vs surgical restriction
• Bariatric surgery vs GLP-1s — the surgery-vs-drug comparison endoscopy sits between
• Bariatric surgery vs GLP-1: the decision guide — how to choose across all the options
• How much is weight-loss surgery? — the cost math endoscopic procedures compete on
• GLP-1s after bariatric surgery for weight regain — the procedure-plus-medication approach in practice

Important disclaimer. This article is educational and does not constitute medical advice. Endoscopic bariatric procedures are invasive and carry real risks; suitability depends on your BMI, health, and goals, and must be assessed by a qualified bariatric endoscopist or obesity-medicine physician. Cross-trial comparisons with GLP-1 drugs and with surgery are not head-to-head and should be interpreted with care. Cost statements are general US market context, not trial-derived. Do not start, stop, or change any treatment based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-07-01.

Last verified: 2026-07-01. Next review: every 12 months, or sooner if a head-to-head endoscopic-vs-GLP-1 trial or a major long-term outcome study is published.